Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5206
Abstract: The FDA has granted Breakthrough Therapy Designation (BTD) for talquetamab, which targets both GPRC5D on multiple myeloma cells and CD3 on T-cells, for treating adult patients with relapsed or refractory multiple myeloma. Results showed that…
read more here.
Keywords:
anti cd3;
gprc5d bispecific;
gprc5d;
cd3 gprc5d ... See more keywords